Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 2995-3008

  Young, Mary Beth ^a   Barrow, James C ^a   Glass, Kristen L ^a   Lundell, George F ^a   Newton, Christina L ^a   Pellicore, Janetta M ^a   Rittle, Kenneth E ^a   Selnick, Harold G ^a   Stauffer, Kenneth J ^a   Vacca, Joseph P ^a   Williams, Peter D ^a   Bohn, Dennis ^a   Clayton, Franklin C ^a   Cook, Jacquelynn J ^a   Krueger, Julie A ^a   Kuo, Lawrence C ^a   Lewis, S Dale ^a   Lucas, Bobby J ^a   McMasters, Daniel R ^a   Miller Stein, Cynthia ^a   Pietrak, Beth L ^a   Wallace, Audrey A ^a   White, Rebecca B ^a   Wong, Bradley ^a   Yan, Youwei ^a   Nantermet, Philippe G ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLAMINE DERIVATIVE; HETEROCYCLIC COMPOUND; PHOSPHORUS; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS; THROMBOEMBOLISM;

BENZYLAMINES; BINDING SITES; HETEROCYCLIC COMPOUNDS; MODELS, MOLECULAR; PYRAZINES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; THIADIAZOLES; THROMBIN; TRIAZOLES;

EID: 2542523899     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030303e     Document Type: Article

References (23)

1. Thrombosis in Cardiovascular Disorders; Fuster, V., Verstraete, M., Eds. ; W. B. Saunders Co.: Philadelphia, 1992.
2. Pharmacology; Brenner, G. M.; W. B. Saunders Co.: Philadelphia, 2000.
3. Anand, S. Direct Thrombin Inhibitors. Haemostasis 1999, 29 (Suppl. 1), 76-78.
4. Sorbera, L. A.; Bayes, M.; Castaner, J.; Silvestre, J. Melagatran and Ximelagatran. Drugs Future 2001, 26 (12), 1155-1170.
5. Marder, V. J. Thrombolytic Therapy: 2001. Blood Rev. 2001, 15, 143-157.
6. Bajusz, S.; Szell, E.; Bagdy, D.; Barabas, E.; Horvath, G.; Dioszegi, M. ; Fittler, Z.; Szabo, G.; Juhasz, A.; Tomori, E.; Szilagyi, G. Highly Active and Selective Anticoagulants: D-Phe-Pro-Arg-H, a Free Tripeptide Aldehyde Prone to Spontaneous Inactivation, and Its Stable N-Methyl Derivative, D-MePhe-Pro-Arg-H. J. Med. Chem. 1990, 33, 1729-1735.
7. Coburn, C. A. Small-molecule Direct Thrombin Inhibitors: 1997-2000. Exp. Opin. Ther. Patents 2001, 11, 1-18.
8. 3.
9. Lumma, W. C.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T. ; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. Design of Novel, Potent, Noncovalent Inhibitors of Thrombin with Nonbasic P-1 Substructures: Rapid Structure-Activity Studies by Solid-Phase Synthesis. J. Med. Chem. 1998, 41, 1011-1013.
10. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I.-W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position. J. Med. Chem. 1998, 41, 3210-3219.
11. Sanderson, P. E. J.; Lyle, T. A.; Cutrona, K. J.; Dyer, D. L.; Dorsey, B. D.; McDonough, C. M.; Naylor-Olsen, A. M.; Chen, I.-W.; Chen, Z.; Cook, J. J.; Cooper, C. M.; Gardell, S. J.; Hare, T. R.; Krueger, J. A.; Lewis, S. D.; Lin, J. H.; Lucas, B. J.; Lyle, E. A.; Lynch, J. J.; Stranieri, M. T.; Vastag, K.; Yan, Y.; Shafer, J. A.; Vacca, J. P. Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates. J. Med. Chem. 1998, 41, 4466-4474.
12. Burgey, C. S.; Robinson, K. A.; Lyle, T. A.; Sanderson, P. E. J.; Lewis, S. D.; Lucas, B. J.; Krueger, J. A.; Lyle, E. A.; Stranieri, M. T.; Holahan, M. A.; Sitko, G. R.; Cook, J. J.; Wallace, A. A.; Clayton, F.; Bohn, D.; Leonard, Y.; Detwiler, T.; Lynch, J. J.; Williams, P. D.; Coburn, C. A.; Dorsey, B. D.; McMasters, D. R.; McDonough, C. M.; Sanders, W. M.; Gardell, S. J.; Shafer, J. A.; Vacca, J. P. Metabolism Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines. J. Med. Chem. 2003, 46, 461-473.
13. Lewis, S. D.; Ng, A. S.; Lyle, E. A.; Mellott, M. J.; Appleby, S. D.; Brady, S. F.; Stauffer, K. J.; Sisko, J. T.; Mao, S.-S.; Veber, D. F.; Nutt, R. F.; Lynch, J. J.; Cook, J. J.; Gardell, S. J.; Shafer, J. A. Inhibition of Thrombin by Peptides Containing Lysyl-α-Keto Carbonyl Derivatives. Thromb. Haemost. 1995, 74, 1107-1112.
14. Breinlinger, E. C.; Keenan, C. J.; Rotello, V. M. Modulation of Flavin Recognition and Redox Properties Through Donor Atom-π Interactions. J. Am. Chem. Soc. 1998, 120, 8606-8609.
15. Rotello, V. M. The Donor Atom-pi Interaction of Sulfur with Flavin. A Density Functional Investigation. Heteroat. Chem. 1998, 9 (7), 605-606.
16. Burgey, C. S.; Robinson, K. A.; Lyle, T. A.; Nantermet, P. G.; Selnick, H. G.; Isaacs, R. C. A.; Lewis, S. D.; Lucas, B. J.; Krueger, J. A.; Singh, R.; Miller-Stein, C.; White, R. B.; Wong, B.; Lyle, E. A.; Stranieri, M. T.; Cook, J. J.; McMasters, D. R.; Pellicore, J. M.; Pal, S.; Wallace, A. A.; Clayton, F. C.; Bohn, D.; Welsh, D. C.; Lynch, J. J.; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S. J.; Shafer, J. A.; Vacca, J. P. Pharmacokinetic Optimization of 3-Amino-6-chloropyrazinone Acetamide Thrombin Inhibitors. Implementation of P3 Pyridine N-Oxides to Deliver an Orally Bioavailable Series Containing P1 N-Benzylamides. Bioorg. Med. Chem. Lett. 2093, 13, 1353-1357.
17. Tucker, T. J.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Lucas, B. J.; Baskin, E. P.; Woltmann, R.; Lynch, J. J.; Lyle, E. A.; Appleby, S. D.; Chen, I.-W.; Dancheck, K. B.; Vacca, J. P. Potent Noncovalent Thrombin Inhibitors That Utilize the Unique Amino Acid D-Dicyclohexylalanine in the P3 Position. Implications on Oral Bioavailability and Antithrombotic Efficacy. J. Med. Chem. 1997, 40, 1565-1569.
18. Sanderson, P. E. J.; Cutrona, K. J.; Dyer, D. L.; Krueger, J. A.; Kuo, L. C.; Lewis, S. D.; Lucas, B. J.; Yan, Y. Small, Low Nanomolar, Noncovalent Thrombin Inhibitors Lacking a Group to Fill the 'Distal Binding Pocket'. Bioorg. Med. Chem. Lett. 2003, 13, 161-164.
19. Rittle, K. E.; Barrow, J. C.; Cutrona, K. J.; Dyer, D. L.; Glass, K. L.; Krueger, J. A.; Kuo, L.; Lewis, S. D.; Lucas, B. J.; McMasters, D. R.; Morrissette, M. M.; Nantermet, P. G.; Newton, C. L.; Sanders, W. M.; Yan, Y.; Vacca, J. P.; Selnick, H. G. Unexpected Enhancement of Thrombin Inhibitor Potency with o-Aminoalkylbenzylamides in the P1 position. Bioorg. Med. Chem. Lett. 2003, 13, 3477-3482.
20. Sanderson, P. E. J. Chapter 8. Anticoagulants: Inhibitors of Thrombin and Factor Xa. Annu. Rep. Med. Chem. 2001, 36, 79-88.
21. Burgey, C. S.; Isaacs, R. C.; Dorsey, B. D.; Robinson, K. A.; Staas, D. D.; Sanderson, P. E. J.; Barrow, J. C. Pyrazinone Thrombin Inhibitors. United States Patent US 6,387,911 B1, May 14, 2002.
22. DeVita, R. J.; Bochis, R.; Frontier, A. J.; Kotliar, A.; Fisher, M. H.; Schoen, W. R.; Wyvratt, M. J.; Cheng, K.; Chan, W. W.-S.; Butler, B.; Jacks, T. M.; Hickey, G. J.; Schleim, K. D.; Leung, K.; Chen, Z.; Chiu, S.-H. L.; Feeney, W. P.; Cunningham, P. K.; Smith, R. G. A Potent, Orally Bioavailable Benzazepinone Growth Hormone Secretagogue. J. Med. Chem. 1998, 41, 1716-1728.
23. Sakamoto, T.; Kaneda, S.-I.; Nishimura, S.; Yamanaka, H. Site-Selectivity in the Cyanation of 3-Substituted Pyridine 1-Oxides with Trimethylsilanecarbonitrile. Chem. Pharm. Bull. 1985, 33 (2), 565-571.